(NASDAQ: SRNE, "Sorrento") released positive Phase 1b trial data ( NCT03542838) of resiniferatoxin (RTX) with completed Day 84 effectiveness data (end-point analysis) for all patients and completed six-month follow-ups in all doses for all patients enrolled, with no negative safety signal as of September 2020.ĭr. 28, 2020 (GLOBE NEWSWIRE) - Sorrento Therapeutics, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |